SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is gaining traction among traders due to its low float, regained NASDAQ compliance, and recent contract wins, sparking discussions about a potential short squeeze. Community members are comparing it to other Hong Kong-based stocks that have recently experienced significant gains, with some highlighting the high cost to borrow as a catalyst. Traders are actively monitoring its potential for a substantial move.

"What's Updog?" is a Community Led token.

UpDog

UpDog CRYPTO is trending, and the community is actively engaging with a playful, meme-driven narrative centered around the question, "What's UpDog?". Built on Solana, UpDog has a dedicated community, and some are highlighting its long-term presence in the meme coin space.

Stonks is the first ever memecoin on the Solana blockchain.   Verifiably deployed in block 71935764 on April 02, 2021 22:10:10 UTC.  On 2024-11-24 members of the community banded together and purchased the website, Twitter, GitHub and developer coins from the original team, making it 100% community owned.  Liquidity has been locked and the community is committed to ensuring the revival of the project

Stonks

Stonks ($STNK) is trending as the first memecoin on Solana, backed by the IP rights to the iconic "Stonks" meme, and is gaining attention amidst the current meme coin season. The community emphasizes its provenance and unique position as the original meme coin on Solana, with some anticipating a rise to 1 $STNK = 1 $ETH. Community members highlight the token's strong community and proven ability to survive a community takeover.

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

$FIRECOIN is trending amid community discussions about potential scams and pump-and-dump schemes, with some users reporting difficulty selling. Despite the concerns, some traders are noting significant gains and momentum, particularly among Phantom Wallet users. Conversations often mention its association with the Solana blockchain.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending due to a mix of factors, including news of Tim Cook's commitment to increased investment in China amidst U.S. trade tensions.  The community is also buzzing about potential new product announcements and the company's AI strategy, with some analysts highlighting strong iPhone sales data.  However, concerns about China's role in Apple's supply chain and competition from other tech giants remain focal points.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as investors are actively discussing the start of Gravity SUV deliveries and a new partnership with Uber, while also expressing concerns about the company's financial health and potential dilution. The community is debating whether the company can scale production effectively and achieve profitability amidst a competitive EV market. Sentiment is mixed, with some highlighting the quality of Lucid's vehicles, while others express frustration with the stock's performance.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems ($DCTH) is trending as investors analyze CHOPIN trial data heading to #esmo2025. The community is weighing the potential for significant upside, buyout possibilities, and increased volatility. Some investors believe recent data shows the combination therapy had a significant increase in two-year survival.

Concord Medical Services Holdings Ltd. engages in the provision of operation of radiotherapy and diagnostic imaging centers. It operates through Network Business and Hospital Business segments. It provides radiotherapy and diagnostic equipment leasing services to hospitals, and sale of medical equipment and the provision of radiotherapy and diagnostic equipment leasing and management services to hospitals. The company was founded on November 27, 2007 and is headquartered in Beijing, China.

Concord Medical Services - ADR

Concord Medical Services Holdings Limited

CCM is trending due to its association with other low-float Hong Kong stocks that have experienced significant short squeezes. Traders are actively discussing its potential for a similar parabolic move, drawing comparisons to $YGMZ and $LNKS. The community is also watching for news catalysts related to the company's operations in cancer therapy.

SPX6900 is an advanced blockchain cryptography token coin capable of limitless possibilities and scientific utilization.

SPX6900

SPX6900 is trending as community members express excitement about recent gains and potential future growth, drawing comparisons to early Dogecoin and GME. The community emphasizes a long-term vision, urging others to "stop trading and believe in something", and highlighting the potential for SPX to flip the stock market. Conversations also reference Elon Musk potentially referencing the coin's mascot, further fueling speculation and interest.

VirnetX Holding Corp. engages in the provision of Internet security software and technology solutions to facilitate secure network communications, including 5G and 4G LTE. Its products include War Room, Gabriel secure gateway, collaboration suite, secure domains, secure communication platform, and connection technology. The company was founded on August 5, 2005 and is headquartered in Zephyr Cove, NV.

Virnetx Holding Corp

VirnetX (VHC) is trending amid discussions of a new government contract and treasury strategies, potentially leading to a short squeeze. The community highlights the company's strong cash position and low float, while anticipating news and a possible 'monster' run. Speculation centers around VirnetX's potential to capitalize on the cybersecurity sector, especially with government partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioNTech SE (BNTX) announced on Friday that a late-stage trial, conducted by its partner Duality Biologics in China, has met its primary endpoint of progression-free survival at a pre-specified interim analysis. The trial is evaluating Trastuzumab Pamirtecan versus Trastuzumab Emtansine in patients with certain types of breast cancer.Shares of the company traded 10% higher in the pre-market session on Friday. The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate">trial</a> enrolled 228 patients with HER2-positive unresectable or metastatic breast cancer, an aggressive form of the disease that has spread and cannot be surgically removed, who previously received Trastuzumab and a taxane-based chemotherapy.On Stocktwits, retail sentiment around BNTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_8_57_36_AM_png_5a9988a80e.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.DualityBio Global Medical Officer Hua Mu noted that breast cancer has a high incidence rate in China, with over 350,000 new cases annually.“Together with our partner BioNTech, we plan the development of Trastuzumab Pamirtecan in further tumor types towards BLA application in other regions including the United States and the European Union to maximize its potential for patients around the world,” Mu said.BioNTech also noted that this is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023. The collaboration aims to accelerate the development of differentiated antibody drug-conjugate therapeutics for solid tumors.BioNTech holds global commercial rights for Trastuzumab Pamirtecan, while DualityBio has commercial rights for Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.BNTX stock is down by 9% this year but up by about 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-proposes-whopping-1-trillion-pay-package-for-ceo-elon-musk/chwIJkaRdpr">Tesla Proposes Whopping $1 Trillion Pay Package For CEO Elon Musk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

Why Did BioNTech Stock Surge 10% Pre-Market Today?

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.

Equity

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.


U.S.-listed shares of Ascendis Pharma climbed more than 7% in Thursday’s premarket session, setting the stage for their best open since early January.Late on Wednesday, the company reported better-than-expected fourth-quarter results and announced a share repurchase program.The Danish biopharma company posted Q4 revenue of €173.92 million ($180.6 million), up from €137.7 million a year ago, while its loss per share narrowed to €0.64 from €1.53.&nbsp;CEO Jan Mikkelsen said the company is “positioned to continue strong revenue growth in 2025 and beyond,” citing Yorvipath’s early U.S. momentum and SkyTROFA’s leadership in the domestic growth hormone market.&nbsp;Ascendis also confirmed plans to submit regulatory filings for TransCon CNP as a treatment for children with achondroplasia.The board also authorized up to $18.25 million for repurchases of its American depository receipt shares.&nbsp;On Stocktwits, message volume for Ascendis spiked, with several posts indicating optimism over the guidance and Yorvipath’s growth.<stembedurl>https://stocktwits.com/Pika_Capital/message/604018998</stembedurl><stembedurl>https://stocktwits.com/CrispDry/message/603879227</stembedurl>BofA Securities on Thursday lowered its price target on Ascendis shares to $192 from $203 while maintaining a ‘Buy’ rating.&nbsp;The firm adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp, but reiterated Ascendis as a “top pick for 2025” with projected peak sales of €2.9 billion.Yorvipath recently became the only approved U.S. treatment for hypoparathyroidism after Takeda discontinued Natpara production due to supply issues.Despite the day’s gains, Ascendis shares remain down over 10% in the past year and trade about 54% below the average analyst target of $193.49, according to Koyfin data.&nbsp;&nbsp;The company’s stock has a short interest of 5.4%.(1 Euro=$1.04)For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

T. ROWE PRICE CAPITAL APPRECIATION FUND ESTABLISHES NEW RECORD FOR PERFORMANCE CONSISTENCY

T. ROWE PRICE CAPITAL APPRECIATION FUND ESTABLISHES NEW RECORD FOR PERFORMANCE CONSISTENCY T. ROWE PRICE CAPITAL APPRECIATION FUND ESTABLISHES NEW RECORD FOR PERFORMANCE CONSISTENCY PR Newswire...

T. Rowe Price ExchangeTraded Funds Inc - T. Rowe Price Capital Appreciation Equity ETF

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$38.10
Prev Close	$37.79
Open	$37.75
Dividend Yield	N/A
50-Day Moving Average	$37.22
Beta	N/A
Avg. Volume	888,135.71
PE Ratio	N/A

52-Week High	$38.68
52-Week Low	$28.28
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

TCAF
T Rowe Price Capital Appreciation Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest TCAF News

TCAFT Rowe Price Capital Appreciation Equity ETF